A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin shows distinctive biological and clinical features. Based on the use of a one-mutation mathematical model, this study supports the hypothesis that a single genetic event, the NPM1 mutation, is sufficient to cause this type of leukemia. Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features. Experimental evidence of the oncogenic potential of the nucleophosmin mutant is, however, still lacking, and it is unclear whether other genetic lesion(s), e.g. FLT3 internal tandem duplication, cooperate with NPM1 mutations in acute myeloid leukemia development. An analysis of age-specific incidence, together with mathematical modeling of acute myeloid leukemia epidemiology, can help to uncover the number of genetic events needed to cause leukemia. We collected data on age at diagnosis of acute myeloid leukemia patients from five European Centers in Germany, The Netherlands and Italy, and determined the age-specific incidence of AML with mutated NPM1 (a total of 1,444 cases) for each country. Linear regression of the curves representing age-specific rates of diagnosis per year showed similar slopes of about 4 on a double logarithmic scale. We then adapted a previously designed mathematical model of hematopoietic tumorigenesis to analyze the age incidence of acute myeloid leukemia with mutated NPM1 and found that a one-mutation model can explain the incidence curve of this leukemia entity. This model fits with the hypothesis that NPMc+ acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele.

[1]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[2]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[3]  M. Vickers.  JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation. , 2007, Blood.

[4]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[5]  M. Vickers.  Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data , 1996, British journal of haematology.

[6]  L. Pasqualucci,et al.  NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? , 2008, Leukemia.

[7]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[8]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[9]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[10]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[11]  E Georg Luebeck,et al.  Multistage carcinogenesis and the incidence of colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Falini,et al.  Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.

[13]  J. Clohessy,et al.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. , 2008, Blood.

[14]  M. Yao,et al.  Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.

[15]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[16]  K. Skårberg.  Cellularity and cell proliferation rates in human bone marrow. IV. Studies on bone marrow cellularity and erythrokinetics in hypoproliferative anaemia. , 2009, Acta medica Scandinavica.

[17]  B Falini,et al.  In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML , 2008, Leukemia.

[18]  S. Frank.  Age-specific incidence of inherited versus sporadic cancers: a test of the multistage theory of carcinogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Falini.  Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities? , 2007, Leukemia & lymphoma.

[20]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[21]  W. Hiddemann,et al.  The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. , 2005, The Journal of clinical investigation.

[22]  J. Clohessy,et al.  The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence , 2007, Oncogene.

[23]  M. Yao,et al.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.

[24]  Steven A Frank,et al.  Age-Specific Acceleration of Cancer , 2004, Current Biology.

[25]  Pamela Casey.  Brief Reports , 1983, Violence and Victims.

[26]  N. Bolli,et al.  Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation , 2007, Leukemia.

[27]  M. Shiseki,et al.  Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities , 2007, Leukemia & lymphoma.

[28]  S. Pileri,et al.  Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice , 2008, Haematologica.

[29]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[30]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[31]  A. W. F. Edwards,et al.  The statistical processes of evolutionary theory , 1963 .

[32]  N. Yoo,et al.  Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[33]  C. S. Swindle,et al.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. , 2008, Blood.

[34]  K. Skårberg.  Cellularity and cell proliferation rates in human bone marrow. I. An in vivo method to estimate the total marrow cellularity in man. , 2009, Acta medica Scandinavica.

[35]  N. Bolli,et al.  Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif , 2007, Leukemia.

[36]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[37]  Peter Guttorp,et al.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. , 2002, Blood.

[38]  J. Downing,et al.  Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias , 2007, Leukemia.

[39]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[40]  Martin A Nowak,et al.  The age incidence of chronic myeloid leukemia can be explained by a one-mutation model , 2006, Proceedings of the National Academy of Sciences.

[41]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[42]  Myriam Alcalay,et al.  Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. , 2006, Blood.

[43]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[44]  Brunangelo Falini,et al.  Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. , 2007, Haematologica.

[45]  R. Gallagher.  Dueling mutations in normal karyotype AML , 2005 .

[46]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[47]  Brunangelo Falini,et al.  Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. , 2007, Cancer research.